(-0.05%) 5 211.25 points
(-0.05%) 39 008 points
(-0.06%) 18 188 points
(-0.51%) $77.98
(0.14%) $2.21
(0.15%) $2 327.70
(0.31%) $27.63
(0.03%) $988.70
(0.18%) $0.931
(0.50%) $10.95
(0.17%) $0.801
(0.01%) $91.45
Live Chart Being Loaded With Signals
Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India...
Stats | |
---|---|
本日の出来高 | 10 471.00 |
平均出来高 | 101 780 |
時価総額 | 3.91B |
EPS | INR0 ( 2024-02-08 ) |
次の収益日 | ( INR0 ) 2024-05-20 |
Last Dividend | INR2.50 ( 1996-08-12 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -96.18 |
ATR14 | INR0.344 (0.29%) |
ボリューム 相関
Lyka Labs Limited 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Lyka Labs Limited 相関 - 通貨/商品
Lyka Labs Limited 財務諸表
Annual | 2022 |
収益: | INR930.73M |
総利益: | INR555.18M (59.65 %) |
EPS: | INR-4.57 |
FY | 2022 |
収益: | INR930.73M |
総利益: | INR555.18M (59.65 %) |
EPS: | INR-4.57 |
FY | 2022 |
収益: | INR1.84B |
総利益: | INR1.30B (70.97 %) |
EPS: | INR13.57 |
FY | 2021 |
収益: | INR671.07M |
総利益: | INR291.40M (43.42 %) |
EPS: | INR-4.07 |
Financial Reports:
No articles found.
Lyka Labs Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR2.50 | 1995-09-11 |
Last Dividend | INR2.50 | 1996-08-12 |
Next Dividend | INR0 | N/A |
Payout Date | 1996-10-01 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | INR5.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.84 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 2.22 | |
Div. Directional Score | 1.072 | -- |
Year | Amount | Yield |
---|---|---|
1995 | INR0 | 0.00% |
1996 | INR0 | 0.00% |
1997 | INR0 | 0.00% |
1998 | INR0 | 0.00% |
1999 | INR0 | 0.00% |
2000 | INR0 | 0.00% |
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
STARPAPER.NS | Dividend Junior | 2023-09-15 | Sporadic | 22 | 1.19% | |
MUNJALAU.NS | Dividend Junior | 2023-08-24 | Sporadic | 19 | 1.47% | |
HINDCOMPOS.NS | Dividend Junior | 2023-09-22 | Annually | 23 | 0.50% | |
BODALCHEM.NS | Dividend Junior | 2023-09-22 | Annually | 14 | 0.38% | |
RELAXO.NS | Dividend Junior | 2023-08-17 | Annually | 14 | 0.17% | |
KRBL.NS | Dividend Junior | 2023-08-25 | Annually | 23 | 0.61% | |
FCL.NS | Dividend Junior | 2023-09-08 | Annually | 10 | 0.22% | |
ANANTRAJ.NS | Dividend Junior | 2023-06-27 | Annually | 18 | 0.22% | |
TATACOFFEE.NS | Dividend Junior | 2023-05-15 | Annually | 23 | 0.85% | |
NIACL.NS | No Dividend Player | 2023-09-07 | Sporadic | 7 | 0.44% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0336 | 1.500 | -0.672 | -1.007 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.125 | 1.500 | -2.50 | -3.75 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0.735 | 1.000 | -0.839 | -0.839 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.01 | 2.00 | 7.33 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 8.01 | 2.00 | 6.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.614 | 1.000 | 3.11 | 3.11 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0464 | 1.000 | -1.072 | -1.072 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.0770 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -110.66 | 1.000 | -10.00 | 0 | [1 - 100] |
returnOnEquityTTM | -0.125 | 2.50 | -1.606 | -3.75 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 8.01 | 2.00 | 7.33 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.01 | 2.00 | 7.33 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.828 | 1.500 | 7.81 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.251 | 1.000 | 6.23 | 0 | [0.1 - 0.5] |
Total Score | 2.22 |
Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。